Stocks To Watch Today on March 17, 2025: IndusInd Bank, IRFC, Infosys, Wipro, and More in Focus

Indian markets are expected to be impacted today. At 7:25 AM, GIFT Nifty futures were up by 171 points at 22,589.50.

In the previous session, the Sensex dropped by 200.85 points (0.27%) to 73,828.91, while the Nifty50 fell by 73.30 points (0.33%) to 22,397.20.

Here are the key stocks to watch today on March 17, 2025:

IndusInd Bank

The Reserve Bank of India (RBI) has stepped in to dismiss speculation surrounding IndusInd Bank’s financial health, reaffirming its strong financial position. According to the central bank, IndusInd Bank remains well-capitalised, reporting a Capital Adequacy Ratio of 16.46% and a healthy Provision Coverage Ratio of 70.20% for the December 2024 quarter. Additionally, the bank’s Liquidity Coverage Ratio is robust at 113%, indicating overall stability.

Infosys

Infosys McCamish Systems, a subsidiary of Infosys, has agreed to settle six class-action lawsuits in the U.S. stemming from a cyber incident in November 2023. The settlement, valued at $17.5 million, was reached through mediation on March 13, 2025.

IRFC

Indian Railway Finance Corporation (IRFC) has scheduled a board meeting on March 17 to consider the declaration of a second interim dividend for the financial year 2024-25. The company has set March 21 as the record date to determine the eligible shareholders.

Wipro

Wipro is restructuring its Global Business Lines (GBLs) to strengthen its focus on artificial intelligence, cloud, and digital transformation. Effective April 1, 2025, the move aims to streamline operations and enhance alignment with evolving client needs.

NMDC

Mining giant NMDC has scheduled a board meeting on March 17 to consider an interim dividend for the financial year 2024-25. In compliance with SEBI’s insider trading regulations, the company has closed its trading window until March 19.

Zydus Lifesciences

Zydus Lifesciences‘ API Unit 1 in Ankleshwar, Gujarat, has successfully cleared a USFDA inspection with no observations, reaffirming the company’s compliance with international regulatory standards.

Brigade Enterprises

Real estate company Brigade Group has launched its latest residential project, Brigade Eternia, in Yelahanka, Bengaluru. Spanning 14.65 acres, the project features 1,124 residential units with a total built-up area of approximately 2 million square feet across 12 towers, each comprising 2 basements, a ground floor, and 13 to 14 floors.

With an estimated revenue potential of over ₹2,700 crore, the project is set for completion by March 31, 2030. Additionally, the company has launched “Ebony at Brigade Orchards,” a premium joint venture residential project in Devanahalli, Bengaluru.

GR Infraprojects

GR Infraprojects has secured the Agra-Gwalior Greenfield Road project worth ₹4,262.78 crore. Awarded by the National Highways Authority of India (NHAI), the project will be developed under the Build-Operate-Transfer (BOT) toll model.

Shilpa Medicare

Shilpa Pharma Lifesciences Ltd, a wholly owned subsidiary of Shilpa Medicare, a pharmaceutical company, has successfully cleared a USFDA inspection at its Unit-2 facility in Raichur with zero observations.

Conducted from March 10 to March 14, 2025, the inspection concluded without any Form 483 being issued, marking the second consecutive clean inspection at the site.

Power Grid

State-owned Power Grid Corporation has approved an investment of ₹341.57 crore for two new transmission projects. These projects will facilitate power evacuation from the Ratle (850 MW) and Kiru (624 MW) hydroelectric projects in Jammu and Kashmir. The projects are expected to be completed by mid-2026.

Alkem Labs 

Alkem Laboratories announced that the US Food and Drug Administration (USFDA) conducted a Bioresearch Monitoring (BIMO) inspection at its Bioequivalence Center in Taloja, Maharashtra, from March 10 to March 13, 2025. The company disclosed the development in a regulatory filing, confirming the inspection’s completion.

Tejas Network

Tejas Networks has received a financial boost of ₹123.45 crore from the Ministry of Communications under the Production-Linked Incentive (PLI) Scheme for the financial year 2023-24. The incentive supports the telecom gear maker’s growth and manufacturing expansion.

Conclusion

Indian markets are set for a dynamic trading session, influenced by global cues and key corporate developments. Major stocks to watch include IndusInd Bank, Infosys, Wipro, and IRFC, amid regulatory updates, restructuring, and financial settlements.

Additionally, companies like NMDC, Power Grid, and Tejas Networks remain in focus with investment approvals, dividend considerations, and government incentives shaping market sentiment.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

USD/INR: Rupee Remains Stable Amid Global Trade Tensions and Inflation Data for Week Ending March 13, 2025

The Indian rupee closed flat on Thursday, as comforting U.S. inflation data helped offset concerns over escalating global trade tensions that have dampened risk appetite.

The rupee rose to 87 ending with 0.24% gains on Thursday, March 13, 2025.. The 1-month non-deliverable forward (NDF) indicated that the rupee would open at around 87.20-87.22, little changed from its previous close of 87.2075.

Global Factors Influencing the Rupee

The dollar index remained steady at 103.78, supported by an uptick in U.S. bond yields. This stability came despite softer-than-expected U.S. inflation data for February, which showed consumer prices rising less than anticipated.

The data initially raised hopes of Federal Reserve rate cuts, but traders have since scaled back expectations, now pricing in about 70 basis points of cuts in 2025, down from 76 basis points earlier.

Meanwhile, global trade tensions escalated after U.S. President Donald Trump announced a hike in tariffs on all steel and aluminium imports to 25%, vowing to reclaim wealth “stolen” by other countries.

In retaliation, Canada imposed stiff taxes on a range of U.S. products, including textiles, water heaters, beef, and bourbon. The European Union (EU) also announced plans to raise tariffs on American goods such as beef, poultry, bourbon, motorcycles, peanut butter, and jeans.

Domestic Inflation and Economic Data

On the domestic front, India’s retail inflation fell below 4% in February for the first time in six months, reaching a seven-month low of 3.61%. The decline was driven by easing prices of vegetables, eggs, and other protein-rich items.

This drop in inflation has created room for the Reserve Bank of India (RBI) to consider further rate cuts in upcoming policy meetings.

Additionally, the Index of Industrial Production (IIP) showed a rebound in manufacturing activity, with growth accelerating to 5% in January 2025, according to data released by the National Statistics Office (NSO).

Equity Market and Foreign Investor Activity

The domestic equity market witnessed a decline on Wednesday, with the 30-share BSE Sensex ending 200.85 points (0.27%) lower at 73,828.91.

The broader Nifty also settled 73.30 points (0.33%) down at 22,397.20 points. Foreign institutional investors (FIIs) offloaded equities worth Rs 1,627.61 crore on a net basis, according to exchange data.

Oil Prices and Global Market Impact

Brent crude, the global oil benchmark, traded 0.37% lower at $70.69 per barrel in futures trade. The decline in oil prices provided some relief to India, a major oil importer, but global trade tensions and market volatility continue to weigh on investor sentiment.

Conclusion

While the rupee remains resilient amid mixed global cues, the escalating trade war and fluctuating inflation data are key factors to watch.

Domestically, the drop in retail inflation and improved industrial production offer a silver lining, potentially paving the way for further monetary easing by the RBI.

However, the equity market’s performance and foreign investor activity will remain critical indicators of India’s economic trajectory in the coming months.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Shares That Hit Circuit Limits On March 13, 2025, Godfrey Phillips India, Gensol Engineering and More

On March 13, 2025, BSE Sensex closed 0.27% lower at 73,828.91, while Nifty50 fell 0.33% to 22,387.20. Amidst the market volatility, stocks like Refex Industries, Gensol Engineering, and Godfrey Phillips India hit circuit limits, reflecting significant price movements. Check out the full list of stocks hitting circuits today.

Stocks That Hit Upper Circuit on March 13, 2025

Symbol LTP %chng Price Band % Volume(Lakhs) Value(₹ Crores)
Godfrey Phillips India Ltd 5,708.25 5 5 1.35 76.46
International Gemmological Institute India Ltd 310.2 4.99 5 17.62 54.05
C2C Advanced Systems 290.25 4.99 5 7.05 20.42
ITI Ltd 253.36 5 5 2.05 5.17
Hitech Corporation 197.05 20 20 2.59 4.84

Stocks That Hit Lower Circuit on March 13, 2025

Symbol LTP %chng Price Band % Volume(Lakhs) Value(₹ Crores)
Gensol Engineering 262.25 -5 5 9.94 26.28
Oriana Power 1,079.50 -4.99 5 1.66 18.5
Orchid Pharma Ltd 788.55 -5 5 1.49 12.02
Refex Industries Ltd 381.95 -5 5 1.74 6.71
Nibe Ltd 843.45 -5 5 0.45 3.87

Overview of Companies Hitting Circuits Today

  • Refex Industries

On March 12, 2025, Refex Industries share price ended 5% lower at ₹381.95. Refex Industries share price reached a 52-week high of ₹600, and a 52-week low of ₹120.32.

  • Gensol Engineering

On March 12, 2025, Gensol Engineering share price ended 5% lower at ₹600.00. Gensol Engineering’s share price reached a 52-week high of ₹1,125.75, and a 52-week low of ₹261.70.

  • Godfrey Phillips India

On March 12, 2025, Godfrey Phillips India share price ended 4.04% higher at ₹1,811.65. Godfrey Phillips India’s share price reached a 52-week high of ₹8,480.00, and a 52-week low of ₹2,844.45.

  • ITI Ltd

On March 12, 2025, ITI Ltd share price ended 19.99% higher at ₹605.90. ITI Ltd’s share price reached a 52-week high of ₹592.85, and a 52-week low of ₹210.20.

  • Nibe Ltd

On March 12, 2025, Nibe Ltd share price ended 4.25% lower at ₹854. Nibe Ltd’s share price reached a 52-week high of ₹2,245.40, and a 52-week low of ₹843.40.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Debt Funds vs Fixed Deposits – Where to Park Your Money Post-RBI Rate Cut?

The Reserve Bank of India (RBI), in its monetary policy meeting held from February 5 to February 7, 2025, announced a reduction in the policy repo rate from 6.50% to 6.25%. This marks the first change in the rate after remaining unchanged for eleven consecutive meetings spanning nearly five years. The decision, led by the new RBI Governor, Sanjay Malhotra, involves a 25-basis-point cut.

The repo rate is the interest rate at which the RBI lends to commercial banks, influencing borrowing costs for businesses and individuals. A lower repo rate is expected to prompt banks to reduce lending rates, making loans more affordable. However, it could also lead to a decline in fixed deposit (FD) interest rates, impacting investors who rely on FD returns.

Fixed deposits (FDs) and debt mutual funds are two popular investment options, each catering to different financial goals and risk appetites. While FDs offer guaranteed returns with minimal risk, debt mutual funds provide market-linked returns with the potential for higher yields. Here’s a detailed look at both investment options.

What Are Debt Mutual Funds?

Debt mutual funds are investment funds that primarily invest in fixed-income securities such as government bonds, corporate bonds, treasury bills, and money market instruments.

  • Market-Linked Returns:

While relatively stable, returns depend on interest rate movements and bond market performance.

  • Potentially Higher Yields:

Debt funds often provide better returns than traditional FDs, especially in a declining interest rate environment.

  • Liquidity & Flexibility:

Investors can redeem debt mutual fund units anytime, although some funds may have exit loads for short-term withdrawals.

What Are Fixed Deposits?

Fixed deposits, also known as term deposits, are a secure savings option provided by banks and financial institutions. Investors deposit a lump sum for a fixed tenure—ranging from a few months to several years—at a predetermined interest rate.

  • Guaranteed Returns:

The bank assures a fixed interest rate, making FDs a safe choice for conservative investors.

  • Low Risk:

Since FDs are not affected by market fluctuations, they are ideal for individuals seeking stability in their savings.

  • Limited Liquidity:

Early withdrawals from FDs may attract penalties, making them less flexible compared to market-linked investments.

Choosing Between Fixed Deposits and Debt Mutual Funds

The choice between FDs and debt mutual funds depends on an investor’s financial goals, risk tolerance, and investment horizon. While FDs are best suited for risk-averse individuals seeking stable returns, debt mutual funds can be a better option for those willing to take moderate risks for potentially higher gains.

Both options play a vital role in a diversified investment portfolio, balancing stability and growth based on market conditions and personal financial strategies.

Debt Funds Gain Appeal Amid Falling Interest Rates

The rate cut has brought debt mutual funds into the spotlight. When interest rates fall, bonds with higher coupon rates within debt funds become more valuable, as they continue to offer higher returns compared to newly issued bonds.

This increase in bond prices boosts the Net Asset Value (NAV) of debt funds, making them an attractive investment option.

Factors To Remember Before Investing in Debt Funds or Fixed Deposits

Debt funds and fixed deposits are two of the most popular investment options, catering to different financial needs and risk profiles. Here’s a detailed comparison based on risk, returns, liquidity, and tax efficiency:

1. Risk and Reward Ratio 

Debt Mutual Funds: These funds are market-linked and typically offer returns in the range of 7-8%. In favourable market conditions, debt funds can outperform FDs, albeit with moderate risk.

Fixed Deposits: FDs are low-risk investments offering stable returns of around 6-7% annually. Their returns are independent of market fluctuations, making them a safer option for risk-averse investors.

2. Liquidity

Debt Funds: Highly liquid, debt funds can be redeemed at any time. However, some funds may charge an exit load for short-term redemptions.

Fixed Deposits: FDs are less flexible, with early withdrawals often incurring an interest penalty of 0.5-2%.

3. Tax Efficiency

Recent tax changes have levelled the playing field between debt funds and FDs. Both are now taxed according to the investor’s income tax slab rate.

However, debt funds may still offer better post-tax returns for investors in lower tax brackets, especially when invested in tax-saving funds.

Debt Funds Outperform Bank FDs in the Last 2 Years 

According to the news report, over the past 2 years, approximately 215 debt mutual funds have outperformed the 7% interest rate offered by the State Bank of India (SBI) on fixed deposits, showcasing their potential as a lucrative investment option.

Leading the pack, DSP Credit Risk Fund delivered the highest return of 11.65% over the 2 years, followed closely by Aditya Birla SL Credit Risk Fund, which provided a return of 9.45% during the same timeframe.

In the last year alone, the performance of debt mutual funds has been even more impressive, with 254 funds surpassing bank FD rates. Among these, around 18 funds achieved double-digit returns.

Aditya Birla SL Credit Risk Fund emerged as a top performer with a 12.13% return in the past year, while HDFC Long Duration Debt Fund and SBI Long Duration Fund followed with returns of 11.91% and 11.74%, respectively.

Other notable performers over the 2 years include SBI Long Duration Fund, which delivered a 9.44% return, and Aditya Birla SL Long Duration Fund and DSP Strategic Bond Fund, each offering an 8.88% return.

Additionally, Bandhan G-Sec-Constant Maturity Plan and Bandhan G-Sec-Invest posted returns of 8.67% and 8.66%, respectively, while Kotak Savings Fund and Invesco India Medium Duration Fund each provided a 7.01% return during the same period.

Conclusion

The RBI’s decision to cut the repo rate after five years of maintaining the status quo has set the stage for a shift in the investment landscape.

While borrowers may benefit from lower lending rates, investors are likely to find debt mutual funds increasingly attractive, especially in a falling interest rate environment.

However, as with any investment, a balanced and diversified approach remains key to managing risks and optimising returns.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Jubilant Pharmova Subsidiary Jubilant Cadista Receives EIR with VAI Status from USFDA

Drug firm Jubilant Pharmova Ltd announced on Wednesday, March 12, that its subsidiary, Jubilant Cadista Pharmaceuticals Inc., has received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the US Food and Drug Administration (USFDA) for its solid oral formulations facility in Salisbury, Maryland, USA.

USFDA Inspection Successfully Closed

The EIR follows an inspection conducted by the USFDA in January 2025, and with this, the inspection is considered successfully closed. Jubilant Pharmova confirmed the receipt of the USFDA’s communication on March 11, 2025, at 09:27 PM IST.

Despite this positive development, the facility is not expected to manufacture any products, as its manufacturing operations were previously shut down, a decision disclosed by the company on April 18, 2024.

Understanding the VAI Status

The Voluntary Action Indicated (VAI) status is assigned when violations are found during an inspection, but the issues do not warrant further regulatory action from the USFDA. While improvements in Good Manufacturing Practice (GMP) compliance are suggested, they remain voluntary.

Under this classification:

  • The facility can continue selling approved drugs.
  • The company can receive approvals for new drug applications.

USFDA’s Establishment Inspection Report (EIR) Process

Based on the findings of the January 2025 inspection and the company’s response, the USFDA issues an EIR within 30 days of the inspection. This report reflects the agency’s official determination of the facility’s GMP compliance.

The FDA’s Inspection Classification Database categorises inspections under three classifications:

  1. No Action Indicated (NAI) – No significant violations found.
  2. Voluntary Action Indicated (VAI) – Issues identified, but no enforcement action required.
  3. Official Action Indicated (OAI) – Serious violations requiring regulatory intervention.

The VAI classification signals that while some compliance improvements are advised, Jubilant Cadista’s facility is still eligible for regulatory approvals.

Industry Implications

This development provides regulatory clarity for Jubilant Pharmova, ensuring that its Salisbury facility remains compliant with USFDA standards, despite the prior shutdown of manufacturing operations. The EIR further reinforces Jubilant Cadista’s adherence to GMP regulations, which is critical for maintaining trust in its pharmaceutical products.

Stock Performance 

On March 13, 2025, Jubilant Pharmova share price traded 0.14% lower at ₹864.05 at 10:06 AM (IST). Jubilant Pharmova’s share price reached a 52-week high of ₹1,309.00, and a 52-week low of ₹538.80. As per BSE, the total traded volume for the stock stood at 0.47 lakh shares with a turnover of ₹4.19 crore.

At the current price, Jubilant Pharmova shares are trading at a price-to-earnings (P/E) ratio of 361.53x, based on its trailing 12-month earnings per share (EPS) of ₹2.39, and a price-to-book (P/B) ratio of 6.01, according to exchange data.

 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Madras High Court Rejects Thangamayil Jewellery’s ₹70.18 Crore Tax Appeal for AY 2022-23

Thangamayil Jewellery Ltd has announced in an exchange filing that its writ petition challenging a tax demand of ₹70.18 crore has been dismissed by the Madras High Court’s Madurai Bench.

The petition was filed under Article 226 of the Constitution of India, contesting the notice of demand issued under Section 156 of the Income Tax Act, 1961, for the Assessment Year 2022-23.

Legal Challenge Against Tax Demand

Thangamayil Jewellery had approached the Honorable Madras High Court – Madurai Bench seeking relief against the income tax department’s demand for ₹70.18 crore.

The company had filed a writ petition, arguing against the validity of the notice issued under Section 156 of the Income Tax Act, which mandates taxpayers to clear outstanding dues within the stipulated period.

Madras High Court Ruling

On March 11, 2025, the single bench of the Madras High Court – Madurai Bench dismissed the company’s petition. The ruling implies that Thangamayil Jewellery will now have to comply with the income tax department’s demand unless further legal recourse is pursued.

Implications for Thangamayil Jewellery

The dismissal of the writ petition could have significant financial implications for Thangamayil Jewellery, which will now need to address the tax liability.

The company has yet to announce its next course of action regarding the ruling, whether it plans to appeal the decision before a higher bench or seek alternative legal remedies.

Stock Performance

On March 12, 2025, Thangamayil Jewellery share price ended 3.72% lower at ₹1,793.25. Thangamayil Jewellery’s share price reached a 52-week high of ₹2.558.06, and a 52-week low of ₹1,107.62. As per BSE, the total traded volume for the stock stood at 8,643 shares with a turnover of ₹1.55 crores.

At the current price, Thangamayil Jewellery shares are trading at a price-to-earnings (P/E) ratio of 42.58x, based on its trailing 12-month earnings per share (EPS) of ₹42.11, and a price-to-book (P/B) ratio of 9.54, according to exchange data.

 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Zydus Lifesciences’ Zynext Ventures Invests in Illexcor Therapeutics for Sickle Cell Drug Development

Zydus Lifesciences Ltd announced on Wednesday, March 12, that its venture capital arm, Zynext Ventures USA LLC, has invested in Illexcor Therapeutics, a biopharmaceutical company focused on developing next-generation oral therapies for sickle cell disease (SCD).

The investment is part of Zynext Ventures’ strategy to support breakthrough healthcare innovations addressing significant unmet medical needs.

Advancing a First-in-Class Oral Therapy for Sickle Cell Disease

Illexcor Therapeutics is working on a first-in-class oral drug designed to directly target the root cause of sickle cell disease. Their lead candidate, ILX002, is currently in preclinical development and aims to bind to Hemoglobin S, effectively blocking polymerisation and sickling of red blood cells.

This mechanism has the potential to offer a disease-modifying treatment for SCD, a debilitating genetic disorder affecting up to 10 million people worldwide.

Commitment to Addressing Rare and Orphan Diseases

Dr Sharvil Patel, Managing Director of Zydus Lifesciences, emphasised the importance of the investment, stating, “This investment reflects our commitment to patients battling rare and orphan diseases. Recognising the profound impact of sickle cell disease on patients’ lives, we are pleased to support Illexcor in their efforts to develop a novel therapeutic solution addressing this critical unmet medical need.”

Sickle cell disease significantly affects patients’ quality of life and longevity, with an urgent need for highly efficacious oral therapies to manage the condition globally.

Strategic Collaboration to Accelerate Clinical Trials

Illexcor’s CEO, Andrew Fleischman, expressed optimism about the partnership, stating, “We are excited to partner with Zynext Ventures to advance our lead drug ILX002 into clinical trials later this year. We are hopeful that ILX002 will be a transformative treatment not only for SCD patients in the U.S. but also for millions around the globe. Zynext Ventures and Zydus Lifesciences are in a strategic position to help us achieve these goals.”

Stocks Performance 

On March 12, 2025, Zydus Lifesciences’ share price ended 1.21% lower at ₹889. Zydus Lifesciences’ share price reached a 52-week high of ₹1,323.90, and a 52-week low of ₹859.15. As per BSE, the total traded volume for the stock stood at 0.47 lakh shares with a turnover of ₹4.16 crores.

At the current price, Zydus Lifesciences shares are trading at a price-to-earnings (P/E) ratio of 20.49x, based on its trailing 12-month earnings per share (EPS) of ₹43.39, and a price-to-book (P/B) ratio of 5.00, according to exchange data.

 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

India’s Mutual Fund Industry AUM Falls by ₹2.72 Lakh Crore in February, Marking Biggest Drop in 5 Years

The Indian mutual fund industry witnessed a sharp decline in Assets Under Management (AUM) in 5 years as a result of a downturn in the equity market and reduced inflows across most categories.

According to data from the Association of Mutual Funds in India (AMFI), the industry’s AUM fell by ₹2.72 lakh crore in February 2025, bringing the total to ₹64.53 lakh crore.

Mutual Funds AUM Sees Biggest Drop Since March 2020

The latest decline marks the sharpest drop in AUM since March 2020, when the industry recorded its largest-ever month-on-month fall of nearly ₹5 lakh crore.

The selloff during that period was triggered by the COVID-19 pandemic, which led to a 23.3% plunge in the Nifty 50 index in a single month.

Over the years, AUM has experienced significant fluctuations. In June 2022, the industry saw a decline of ₹1.6 lakh crore, while December 2024 recorded a more moderate drop of ₹1.1 lakh crore.

However, February 2025’s ₹2.72 lakh crore slump signals renewed market stress. Data for March 2024 remains unspecified.

Equity Fund Inflows Drop as Market Selloff Continues

Total inflows into equity mutual funds fell 26.5% month-on-month in February 2025, reaching ₹29,242 crore, as per AMFI data.

The broader stock market downturn also impacted the Nifty 50, which recorded its fifth consecutive monthly decline, falling by 6% in February alone. Over the past five months, the benchmark index has lost a cumulative 14.3%, reflecting weakened investor sentiment.

SIP Inflows Remain Steady

Systematic Investment Plan (SIP) inflows for February stood at ₹25,999 crore, reflecting a 1.5% decline. The drop was primarily attributed to the fewer number of trading days in the month rather than a shift in investor behaviour.

Recent Developments in the Mutual Fund Industry

Following a strong performance in 2023, the mutual fund industry continued its growth momentum into 2024, recording a remarkable ₹16.2 lakh crore surge in assets. This expansion was driven by a buoyant equity market, robust economic growth, and rising investor participation.

The industry had surpassed the ₹50-lakh crore AUM milestone in December 2023, adding nearly ₹14 lakh crore to its total assets in just over a year.

However, post-COVID-19, the mutual fund sector has witnessed a decline of over ₹1 lakh crore on only four occasions, highlighting the significance of February 2025’s sharp drop.

Conclusion 

The Indian mutual fund industry’s sharp AUM decline in February 2025 underscores the impact of market volatility and reduced inflows.

While equity fund inflows weakened, SIP investments remained steady. Despite recent setbacks, the industry’s long-term growth trajectory remains positive, driven by rising investor participation and strong economic fundamentals.

 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Nifty Weekly Expiry Today: Manappuram Finance, IndusInd Bank, BSE Under F&O Ban on March 13

The Nifty 50 index witnessed a modest recovery from its intra-day low on Wednesday, March 12, 2025, but remained range-bound ahead of its weekly expiry. The benchmark index fluctuated between 22,577.40 and 22,329.55 levels during the session, reflecting cautious investor sentiment. Despite the recovery, Nifty 50 failed to hold above the crucial 22,500 mark, closing the day with a minor decline of 27.40 points at 22,470.50.

Stocks Under F&O Ban on Nifty’s Weekly Expiry Day

Ahead of the Nifty weekly expiry on Thursday, March 13, 2025, the National Stock Exchange (NSE) has placed one stock under a trading ban in the futures and options (F&O) segment.

The restriction was imposed after the stock exceeded 95% of the market-wide position limit (MWPL). However, while F&O trading remains restricted, the stock remains available for trading in the cash market.

The stocks under the F&O ban for March 13 include:

  • Manappuram Finance

On March 12, 2025, Manappuram Finance’ share price jumped 2.38%, closing at ₹206.35. According to BSE data, the stock recorded a total traded volume of 3.57 lakh shares, translating to a turnover of ₹7.24 crore.

At the current price, Manappuram Finance shares are trading at a price-to-earnings (P/E) ratio of 9.72x, based on its trailing 12-month earnings per share (EPS) of ₹21.23, and a price-to-book (P/B) ratio of 1.57, according to exchange data.

  • IndusInd Bank

On March 12, 2025, IndusInd Bank share price gained 4.38%, closing at ₹684.70. According to BSE data, the stock recorded a total traded volume of 51.90 lakh shares, translating to a turnover of ₹348.49 crore.

At the current price, IndusInd Bank shares are trading at a price-to-earnings (P/E) ratio of 7.38x, based on its trailing 12-month earnings per share (EPS) of ₹92.75, and a price-to-book (P/B) ratio of 0.82, according to exchange data.

  • Hindustan Copper

On March 12, 2025, Hindustan Copper share price ended 0.30% higher at ₹218.85. According to BSE data, the stock recorded a total traded volume of 10.93 lakh shares, translating to a turnover of ₹23.95 crore.

At the current price, Hindustan Copper shares are trading at a price-to-earnings (P/E) ratio of 52.61x, based on its trailing 12-month earnings per share (EPS) of ₹4.16, and a price-to-book (P/B) ratio of 8.79, according to exchange data.

  • SAIL

On March 12, 2025, SAIL share price ended 1.29% lower at ₹106.75. According to BSE data, the stock recorded a total traded volume of 10.52 lakh shares, translating to a turnover of ₹11.21 crore.

At the current price, SAIL shares are trading at a price-to-earnings (P/E) ratio of 22.24x, based on its trailing 12-month earnings per share (EPS) of ₹4.80, and a price-to-book (P/B) ratio of 0.81, according to exchange data.

  • BSE

On March 12, 2025, BSE share price gained 5.13%, closing at ₹4,005. According to NSE data, the stock recorded a total traded volume of 63.28 lakh shares, translating to a turnover of ₹2,521.48 crore.

At the current price, BSE shares are trading at a price-to-earnings (P/E) ratio of 61.09x, based on its trailing 12-month earnings per share (EPS) of ₹69.33, and a price-to-book (P/B) ratio of 13.91, according to exchange data.

Why Are Stocks Under F&O Ban?

The National Stock Exchange (NSE) has placed a stock under its futures and options (F&O) ban after its derivative contracts surpassed 95% of the market-wide position limit (MWPL).

According to the exchange, traders are only allowed to reduce existing positions through offsetting trades, while opening new positions remains prohibited.

Any attempt to increase open positions could result in penal and disciplinary action. Despite the F&O restrictions, the stock remains available for trading in the cash market.

About Nifty Weekly Expiry Day?

Nifty weekly futures and options (F&O) contracts expire every Thursday unless it coincides with a trading holiday, in which case the expiry is advanced to the previous trading session. All contracts are settled at the normal market closing time on expiry day or at a later time as determined by the National Stock Exchange (NSE).

For individual securities, if the last Thursday of the expiry period is a holiday, the expiry is moved to the preceding trading session.

Additionally, in MarketWatch, expiry dates for the final week’s contracts are not displayed separately, as they are classified under monthly contracts. Instead, only the month’s name and the strike price are shown, ensuring consistency in contract classification.

Recent Shift in Expiry Days

The National Stock Exchange (NSE) has announced a major revision in the expiry schedule of Nifty index weekly futures and options (F&O) contracts. Starting April 4, 2025, these contracts will expire on Monday instead of Thursday. Additionally, the expiry for Bank Nifty, FinNifty, Nifty Midcap Select, and Nifty Next50 F&O contracts will also shift to the last Monday of the expiry month.

According to NSE, this change will take effect from April 4, 2025, and all existing contracts will be adjusted to reflect the new expiry schedule at the end of trading on April 3, 2025 (EOD).

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Shares That Hit Circuit Limits On March 12, 2025, E2E Networks, Sepc Ltd and More

On March 12, 2025, BSE Sensex closed 0.10% lower at 74,029.76, while Nifty50 fell 0.12% to 22,470.50. Amidst the market volatility, stocks like Carysil Ltd, Sepc Ltd, and Axiscades Technologies hit circuit limits, reflecting significant price movements. Check out the full list of stocks hitting circuits today.

Stocks That Hit Upper Circuit on March 12, 2025

Symbol LTP %chng Price Band % Volume(Lakhs) Value(₹ Crores)
Sepc Ltd 15.36 20 20 566.13 82.94
Carysil Ltd 605.9 19.99 20 12.88 74.55
OCCL Ltd 90.5 16.56 20 26.35 23.45
E2E Networks 1,811.65 4.04 5 0.85 15.03
Kitex Garments 166.5 4.8 5 4.04 6.56

Stocks That Hit Lower Circuit on March 12, 2025

Symbol LTP %chng Price Band % Volume(Lakhs) Value(₹ Crores)
International Gemmological Ins India 295.45 -0.47 5 26.28 76.71
Diamond Power Infrastructure 89.1 -3.3 5 20.63 18.08
Axiscades Technologies 854 -4.25 5 1.32 11.57
Zinka Logistics Solutions 410.25 -1.91 5 2.25 9.11
Jai Corp 92.96 -5.01 5 9.35 8.85

Overview of Companies Hitting Circuits Today

  • Jai Corp

On March 12, 2025, Jai Corp share price ended 5% lower at ₹92.96. Jai Corp share price reached a 52-week high of ₹438, and a 52-week low of ₹90.49.

  • Sepc Ltd

On March 12, 2025, Sepc Ltd share price ended 20% higher at ₹15.36. Sepc Ltd’s share price reached a 52-week high of ₹33.50, and a 52-week low of ₹12.03.

  • E2E Networks

On March 12, 2025, E2E Networks share price ended 4.04% higher at ₹1,811.65. E2E Networks’s share price reached a 52-week high of ₹5,487.65, and a 52-week low of ₹780.35.

  • Carysil Ltd

On March 12, 2025, Carysil Ltd share price ended 19.99% higher at ₹605.90. Carysil Ltd’s share price reached a 52-week high of ₹1,036, and a 52-week low of ₹486.65.

  • Axiscades Technologies

On March 12, 2025, Axiscades Technologies share price ended 4.25% lower at ₹854. Axiscades Technologies’s share price reached a 52-week high of ₹899.20, and a 52-week low of ₹421.05.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.